Your browser doesn't support javascript.
loading
LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
Wiegmann, H; Valentin, F; Tarinski, T; Liebau, E; Loser, K; Traupe, H; Oji, V.
  • Wiegmann H; Department of Dermatology, University Hospital Muenster, Von-Esmarch-Straße 58, 48149, Muenster, Germany.
  • Valentin F; Department of Dermatology, University Hospital Muenster, Von-Esmarch-Straße 58, 48149, Muenster, Germany.
  • Tarinski T; Department of Dermatology, University Hospital Muenster, Von-Esmarch-Straße 58, 48149, Muenster, Germany.
  • Liebau E; Institute of Zoophysiology, University of Muenster, Schlossplatz 8, 48143, Muenster, Germany.
  • Loser K; Department of Dermatology, University Hospital Muenster, Von-Esmarch-Straße 58, 48149, Muenster, Germany.
  • Traupe H; Department of Dermatology, University Hospital Muenster, Von-Esmarch-Straße 58, 48149, Muenster, Germany.
  • Oji V; Department of Dermatology, University Hospital Muenster, Von-Esmarch-Straße 58, 48149, Muenster, Germany.
Br J Dermatol ; 181(5): 999-1008, 2019 11.
Article en En | MEDLINE | ID: mdl-30801672
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Transglutaminasas / Epidermis / Síndrome de Netherton / Inhibidor de Serinpeptidasas Tipo Kazal-5 Límite: Humans Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Transglutaminasas / Epidermis / Síndrome de Netherton / Inhibidor de Serinpeptidasas Tipo Kazal-5 Límite: Humans Idioma: En Año: 2019 Tipo del documento: Article